MedTrace Logo

Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants

NCT02132572 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2016-09-13

Study results available
· View outcomes & findings →

Summary

Retrospective multi-center, post-marketing study to evaluate the incidence and etiology of reoperations with Allergan Natrelle® Breast Implants in primary augmentation (RANBI)

Conditions

  • Breast Implantation

Interventions

DEVICE

BIOCELL™ Textured 410 Implant

Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • France
  • Germany
  • Israel
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02132572 on ClinicalTrials.gov